Setting traps for NKG2A gives NK cell immunotherapy a fighting chance

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


The equilibrium of signaling through activating and inhibitory receptors dictates whether a given NK cell will execute cellular cytotoxicity. In this issue of the JCI, Kamiya et al. describe a novel approach to efficiently inhibiting surface expression of the inhibitory receptor CD94/NK group 2 member A (NKG2A) through retention of the protein in the endoplasmic reticulum. In adoptive transfer experiments into tumor-bearing immunodeficient mice, NKG2Anull NK cells were significantly more effective at eliminating HLA-E–expressing tumor cells than NKG2A+ NK cells. This study provides proof of concept for a new immunotherapeutic approach using NKG2Anull NK cells.

Original languageEnglish (US)
Pages (from-to)1839-1841
Number of pages3
JournalJournal of Clinical Investigation
Issue number5
StatePublished - May 1 2019

Bibliographical note

Funding Information:
We would like to acknowledge the following sources of NIH funding: K99/R00 HL123638 (to FC) and P01 CA111412, P01 CA65493, and R35 CA197292 (to JSM).

Publisher Copyright:
© 2019, American Society for Clinical Investigation.


Dive into the research topics of 'Setting traps for NKG2A gives NK cell immunotherapy a fighting chance'. Together they form a unique fingerprint.

Cite this